- Home
- OSTX vs VERV Comparison
OSTX vs VERV Comparison
Compare OSTX & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- VERV
- Stock Information
- Founded
- OSTX 2018
- VERV 2018
- Country
- OSTX United States
- VERV United States
- Employees
- OSTX N/A
- VERV N/A
- Industry
- OSTX
- VERV Medicinal Chemicals and Botanical Products
- Sector
- OSTX
- VERV Health Care
- Exchange
- OSTX NYSE
- VERV Nasdaq
- Market Cap
- OSTX 45.0M
- VERV 384.2M
- IPO Year
- OSTX 2024
- VERV 2021
- Fundamental
- Price
- OSTX $1.53
- VERV $4.45
- Analyst Decision
- OSTX Strong Buy
- VERV Strong Buy
- Analyst Count
- OSTX 3
- VERV 6
- Target Price
- OSTX $18.00
- VERV $25.75
- AVG Volume (30 Days)
- OSTX 345.0K
- VERV 2.9M
- Earning Date
- OSTX 05-16-2025
- VERV 05-14-2025
- Dividend Yield
- OSTX N/A
- VERV N/A
- EPS Growth
- OSTX N/A
- VERV N/A
- EPS
- OSTX N/A
- VERV N/A
- Revenue
- OSTX N/A
- VERV $59,613,000.00
- Revenue This Year
- OSTX N/A
- VERV $6.18
- Revenue Next Year
- OSTX N/A
- VERV N/A
- P/E Ratio
- OSTX N/A
- VERV N/A
- Revenue Growth
- OSTX N/A
- VERV 271.44
- 52 Week Low
- OSTX $1.12
- VERV $2.87
- 52 Week High
- OSTX $7.00
- VERV $9.31
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- VERV 47.78
- Support Level
- OSTX N/A
- VERV $3.89
- Resistance Level
- OSTX N/A
- VERV $4.63
- Average True Range (ATR)
- OSTX 0.00
- VERV 0.41
- MACD
- OSTX 0.00
- VERV 0.02
- Stochastic Oscillator
- OSTX 0.00
- VERV 47.06
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.